Krystal Biotech, Inc. (KRYS) Q3 2025 10-Q Quarterly Report
Filed: Nov 3, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Krystal Biotech, Inc. (KRYS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Krystal Biotech, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New regulatory risk: FDA label update for VYJUVEK in Sep 2025 expands treatment to birth and allows patient/caregiver administration at home, increasing compliance complexity
- • Material update in clinical risk: Phase 3 IOLITE study for KB803 ocular treatment ongoing with decentralized home dosing; enrollment expected complete by year end
Krystal Biotech, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$98M
▲ +16.6% YoY▲ +1.8% QoQ
Net Income
$79M
▲ +192.0% YoY▲ +107.0% QoQ
Operating Margin
42.5%
▲ +1572bp YoY▲ +155bp QoQ
Net Margin
81.1%
▲ +4873bp YoY▲ +4124bp QoQ
ROE
7.0%
Total Assets
$1.2B
EPS (Diluted)
$2.66
▲ +192.3% YoY▲ +107.8% QoQ
Operating Cash Flow
$40M
▼ -32.6% YoY▼ -24.8% QoQ
Source: XBRL data from Krystal Biotech, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Krystal Biotech, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.